Details of the Drug

General Information of Drug (ID: DMASDQ6)

Drug Name
Brodalumab
Synonyms AMG 827
Indication
Disease Entry ICD 11 Status REF
Plaque psoriasis EA90.0 Approved [1]
Psoriasis vulgaris EA90 Phase 3 [2], [3]
Asthma CA23 Phase 2 [2], [4]
Drug Type
Monoclonal antibody
ADMET Property
Clearance
The clearance of drug is 0.223 L/day [5]
Vd
The volume of distribution (Vd) of drug is 4.62 L [5]
Cross-matching ID
DrugBank ID
DB11776
TTD ID
D05CEO

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin 17 receptor (IL17R) TT69OHW I17RA_HUMAN; I17RB_HUMAN; I17RC_HUMAN; I17RD_HUMAN; I17RE_HUMAN Antagonist [6]
Interleukin-17 (IL17) TTG0MT6 IL17_HUMAN Modulator [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Plaque psoriasis
ICD Disease Classification EA90.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-17 (IL17) DTT IL17A 2.91E-02 -0.16 -0.69
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Brodalumab (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Brodalumab and Siponimod. Multiple sclerosis [8A40] [17]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Brodalumab and Ocrelizumab. Multiple sclerosis [8A40] [18]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Brodalumab and Ozanimod. Multiple sclerosis [8A40] [19]

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7540).
3 ClinicalTrials.gov (NCT02029495) Study of Efficacy, Safety and Effect on Radiographic Progession of Brodalumab in Subjects With Psoriatic Arthritis. U.S. National Institutes of Health.
4 Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis
5 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
6 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal. Br J Dermatol. 2012 Oct;167(4):710-3; discussion 714-5.
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10 Targeting the IL-17-T(H)17 pathway. Nat Rev Drug Discov. 2015 Jan;14(1):11-2.
11 DOI: 10.1136/annrheumdis-2015-eular.4042
12 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
13 Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
14 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
15 Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012 Oct;11(10):763-76.
16 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2294).
17 Cerner Multum, Inc. "Australian Product Information.".
18 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
19 Cerner Multum, Inc. "UK Summary of Product Characteristics.".